Baxter International (BAX) closed at $26.42 on November 10, 2026, unchanged from the previous close, on volume of 3,587,688 shares (30-day average 6,753,951).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | 3 Leg Call/Put Combo Calendar | 30-Oct-2623 P : 26 C|06-Nov-2628 C | 9,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Sun, 8-Nov 8:20 PM ET)
Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
Seeking Alpha News (Sun, 8-Nov 9:05 AM ET)
Baxter’s Q3 2026 results pair 5% organic sales growth with a raised full-year outlook
Market Chameleon (Thu, 29-Oct 4:08 AM ET)
Baxter Reports Third-Quarter 2026 Results
Business Wire (Thu, 29-Oct 7:15 AM ET)
Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
Business Wire (Wed, 7-Oct 4:15 PM ET)
Baxter Releases Inaugural Connected Hospital Report
Business Wire (Wed, 30-Sep 9:00 AM ET)
Baxter Appoints John Rogers Chief Financial Officer
Business Wire (Wed, 19-Aug 8:00 AM ET)
Baxter Announces Pricing for Its Upsized Cash Tender Offers
Business Wire (Tue, 18-Aug 4:56 PM ET)
Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers
Business Wire (Tue, 18-Aug 9:00 AM ET)
Baxter's Q1 2026 Results Show International Gains, Pharmaceutical Strength, and Steady Guidance
Market Chameleon (Thu, 30-Apr 3:36 AM ET)
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Baxter International trades on the NYSE stock market under the symbol BAX.
As of November 11, 2026, BAX stock price declined to $26.24 with 682,424 million shares trading.
BAX has a beta of 1.04, meaning it tends to be more sensitive to market movements. BAX has a correlation of 0.09 to the broad based SPY ETF.
BAX has a market cap of $13.57 billion. This is considered a Large Cap stock.
Last quarter Baxter International reported $3 billion in Revenue and $.58 earnings per share. This beat revenue expectation by $69 million and exceeded earnings estimates by $.06.
In the last 3 years, BAX traded as high as $44.01 and as low as $15.73.
The top ETF exchange traded funds that BAX belongs to (by Net Assets): VTI, VOO, VB, RSP, IVV.
BAX has outperformed the market in the last year with a price return of +48.1% while the SPY ETF gained +12.4%. However, in the short term, BAX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.5% vs -1.7% return in SPY. But in the last 2 weeks, BAX shares have fared better than the market returning +5.3% compared to SPY -1.5%.
BAX support price is $25.68 and resistance is $27.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BAX shares will trade within this expected range on the day.
